

Clinical registry of cancers of the biliary tract

Submission date 26/08/2020	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 17/09/2020	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 27/12/2023	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Biliary Tract Cancers (BTC) are tumours arising from the lining of bile ducts. The subtypes of BTCs have similarities but also important differences that can affect their clinical behaviour. The incidence of BTC is increasing all around the world with regional differences in the distribution of subtypes according to risk factors. The aim of this study is to collect clinical data from patients with a diagnosis of BTC in order to define the characteristics and the overall survival in this population.

Who can participate?

Patients aged over 18 years old with a diagnosis of BTC from 2020 to 2024

What does the study involve?

The study involves collecting clinical information on the course of the disease and the response to different treatments. There is an optional choice to provide a number of blood, urine, bile and tissue samples for the duration of treatment and follow-up.

What are the possible benefits and risks of participating?

There are no specific risks or benefits to participants.

Where is the study run from?

Beatson West of Scotland Cancer Centre (UK)

When is the study starting and how long is it expected to run for?

October 2019 to December 2030

Who is funding the study?

University of Glasgow (UK)

Who is the main contact?

1. Dr Chiara Braconi, chiara.braconi@glasgow.ac.uk
2. Karen Allan, karen.allan.3@glasgow.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr Chiara Braconi

ORCID ID

<https://orcid.org/0000-0003-4835-1259>

Contact details

Beatson West of Scotland Cancer Centre
1053 Great Western Road
Glasgow
United Kingdom
G12 0YN
+44 (0)141 330 3278
chiara.braconi@glasgow.ac.uk

Type(s)

Public

Contact name

Ms Karen Allan

Contact details

Glasgow Oncology Clinical Trials Unit (GO CTU)
Partner in CaCTUS - Cancer Clinical Trials Unit Scotland
Level 0
Beatson West of Scotland Cancer Centre
Gartnavel General Hospital
Glasgow
United Kingdom
G12 0YN
+44 (0)141 301 7959 (internal 57959)
karen.allan.3@glasgow.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

276732

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

IRAS 276732

Study information

Scientific Title

REGBil: Clinical REGistry and molecular characterisation of Biliary tract cancers

Acronym

Reg-Bil

Study objectives

To study overall survival in patients with biliary tract cancers in a prospective fashion.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 02/07/2020, South West - Frenchay Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol. BS1 2NT; UK; +44 (0)207 1048028; frenchay.rec@hra.nhs.uk), ref: 20/SW/0054

Study design

Observational longitudinal study

Primary study design

Observational

Study type(s)

Screening

Health condition(s) or problem(s) studied

Biliary tract cancers

Interventions

At study entry, patients will be asked to give their consent for the team to collect their clinical information on the course of their disease. They will also be asked to provide blood, urine, bile and tissue samples for development of markers of response to drug therapy and generation of mini-tumours in the lab. These samples will be collected over the treatment and potentially up to 5 years from study entry.

Intervention Type

Other

Primary outcome(s)

Overall survival (OS) collected from patient notes up to 5 years from time of diagnosis

Key secondary outcome(s))

Collected from patient notes up to 5 years from time of diagnosis:

1. Disease-free survival (DFS) in patients undergoing radical surgery
2. Chemotherapy outcomes with each line of therapy (response rate, progression-free survival)
3. Proportion, DFS, and OS of subtypes of biliary tract cancers
4. DFS and OS according to subgroups (grouped in intrahepatic and extrahepatic BTC)

Exploratory outcome measures:

1. Feasibility of organoids generation from BTC assessed using fresh tumour tissue at baseline and at time of progression
2. Presence and absolute quantities of circulating DNA, circulating microRNA and other relevant biomarkers measured using digital PCR, every 3 months during the course of treatment and at progression
3. Circulating DNA in bile measured using sequencing technologies at baseline
4. Potential biomarkers of BTC measured using sequencing at baseline
5. Circulating and tissue based biomarkers in BTC measured using metabolomics and proteomic approaches every 3 months during the course of treatment and progression

Completion date

31/12/2030

Eligibility

Key inclusion criteria

1. Aged 18 years or older
2. Patients with radiological or cytological/histological diagnosis of BTC, who have been diagnosed and/or treated at NHS Greater Glasgow and Clyde
3. Informed written consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Medical or psychiatric conditions impairing ability to give informed consent

Date of first enrolment

01/09/2020

Date of final enrolment

30/11/2024

Locations

Countries of recruitment

United Kingdom

Scotland

Study participating centre

Beatson West of Scotland Cancer Centre

1053 Great Western Road

Glasgow

United Kingdom

G12 0YN

Sponsor information

Organisation

NHS Greater Glasgow and Clyde

ROR

<https://ror.org/05kdz4d87>

Funder(s)

Funder type

University/education

Funder Name

University of Glasgow

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Universities (academic only)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

IPD sharing plan summary

Other

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes